Clinical Trial Update: Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I dose-escalation trial of monthly intravenous Ra-223 dichloride in sarcoma (osteosarcoma) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma
• Sarcoma

Drugs mentioned

• Ra-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Sarcoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-02